Journal article
Cardiometabolic risk factor control in black and white people in the United States initiating sodium-glucose co-transporter-2 inhibitors: A real-world study
Olga Montvida, Subodh Verma, Jonathan E Shaw, Sanjoy K Paul
DIABETES OBESITY & METABOLISM | WILEY | Published : 2020
DOI: 10.1111/dom.14164
Abstract
AIMS: To explore cardiometabolic risk profiles, the probability of sustainable control, and the effectiveness of treatment with sodium-glucose co-transporter-2 (SGLT2) inhibitors in black and white adults in the United States with type 2 diabetes. MATERIALS AND METHODS: Using nationally representative US electronic medical records, 72 690 white and 10 004 black adults diagnosed with type 2 diabetes initiating SGLT2 inhibitors during the period 2013 to 2018, continuing it for ≥6 months, and with follow-up of ≥12 months, were identified. Glycated haemoglobin (HbA1c), body weight, systolic blood pressure (SBP) and lipid changes at 6 months, and sustainability of control over 18 months post SGLT..
View full abstractGrants
Funding Acknowledgements
S.K.P. and O.M. conceptualized and designed the study. O.M. conducted the data extraction. O.M. and S.K.P. jointly conducted the statistical analyses. The first draft of the manuscript was developed by O.M. and S.K.P., while S.V. and J.H.S. contributed in the interpretation of results and finalization of the manuscript. S.K.P. and O.M. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Melbourne EpiCentre gratefully acknowledges the support from the National Health and Medical Research Council and the Australian Governments National Collaborative Research Infrastructure Strategy (NCRIS) initiative through Therapeutic Innovation Australia. No separate funding was obtained for this study.